Elecoglipron and Statins PK Study Phase 1 in Healthy Participants

NIH added a new Phase 1 clinical trial registration (NCT07534592) to ClinicalTrials.gov. The study evaluates whether elecoglipron, an investigational drug, affects the pharmacokinetics of atorvastatin and rosuvastatin when co-administered in healthy participants.

Pharmaceutical companies and clinical investigators conducting similar drug interaction studies should monitor this registry for results. Trial sponsors developing drugs with statin co-administration potential may need to consider PK interaction assessment requirements in their development programs.